News

AbbVie is the latest pharma firm to join the UK-led dementia consortium, a £4 million collaboration between academia, charity and the private sector that strives to find new drug treatments for dementia.

Bristol-Myers Squibb and the Dana-Farber Cancer Institute have signed a pact to advance onco-immunology research in to rare cancers.

Community pharmacists must work together to fight government plans to cut community pharmacy funding, a group of 400 pharmacists were told yesterday.

US regulators have rejected Merck & Co’s request to expand the use of its cholesterol busters Zetia and Vytorin.

The first biosimilar version of Pfizer/Amgen’s multi-billion-dollar anti-inflammatory Enbrel (etancerpt) has now been launched in the UK, offering access to a cheaper alternative that could drive down healthcare costs.

Eisai and Charles River Labs are to work together on a range of projects at Eisai’s research and development facilities in Hatfield, UK.

Researchers believe they have made a major breakthrough in cancer treatment, after a small clinical trial showed that engineered T-cells induced complete remission in 94% of terminally ill patients with acute lymphoblastic leukaemia.

NHS England is to invest an extra £1 billion a year into improving mental health services, in line with a wide-reaching package of recommendations made by the Mental Health Taskforce.

The number of new referrals for patients with pulmonary hypertension has jumped 21 percent over the last five years, according to findings of a national audit published by the Health and Social Care Information Centre (HSCIC).

Amgen has launched its multiple myeloma drug Kyprolis in the UK, offering patients the chance to access the first irreversible proteasome inhibitor cleared to treat the rare and aggressive blood cancer.

Lilly has lost the latest round in an ongoing legal fight over patents covering the administration of vitamins given alongside its blockbuster lung cancer drug Alimta (pemexetred).

Merck & Co and Sun Pharmaceutical are winding down their 2011 joint venture focused on developing branded generics for emerging markets outside of India.

UK patients with advanced kidney cancer are being given the opportunity to be treated with Bristol-Myers Squibb’s investigational immunotherapy Opdivo ahead of a licensing decision in Europe.

Novartis group Sandoz has acquired rights to Pfizer’s PF-06438179, a biosimilar of MSD’s Remicade (infliximab), in the 28 countries that form the European Economic Area (EEA), further strengthening its immunology offering.

GlaxoSmithKline and a number of other pharmaceutical companies have been fined £45 million by the UK’s Competition and Markets Authority for anti-competitive conduct relating to the supply of the antidepressant Seroxat (paroxetine).